EUVIMEDSkopri EUVIMED
Open access

Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study

Martin Svaton, Magdalena Knetki-Wroblewska, Petr Hosek, Gabriela Chowaniecova, Jan Spacek, Ondrej Fischer, Ondrej Bilek, Michal Hrnciarik, Diego Kauffmann-Guerrero

Journal of Cancer · 2025-07-01 · 16 (10) · 3015-3023

DOI: 10.7150/jca.113815 ↗

At a glance

Journal article in Journal of Cancer, published on 2025-07-01. Written by Martin Svaton and 8 co-authors. Institution: Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic. Cited 2 times so far (Crossref). The full text is freely available in PubMed Central.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Ebda abstract disponibbli.

Subjects

Author keywords

NSCLCchemotherapyhigh PD-L1 expressionimmunochemotherapy, pembrolizumabreal-world evidence

Authors and institutions

  • Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.
  • Department of Lung Cancer and Chest Tumours Maria Sklodowska-Curie National Research Institute of Cancer, Warsaw, Poland.
  • Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Clinical Oncology, Specialised Hospital of St Zoerardus Zobor, Nitra, Slovakia.
  • Department of oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Department of Respiratory Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

Cite

APA

Svaton, M., Knetki-Wroblewska, M., Hosek, P., Chowaniecova, G., Spacek, J., Fischer, O., Bilek, O., Hrnciarik, M., & Kauffmann-Guerrero, D. (2025). Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study. Journal of Cancer, 16(10), 3015-3023. https://doi.org/10.7150/jca.113815

Vancouver

Svaton M, Knetki-Wroblewska M, Hosek P, Chowaniecova G, Spacek J, Fischer O, et al. Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study. Journal of Cancer. 2025;16(10):3015-3023. doi:10.7150/jca.113815

BibTeX
@article{Svaton2025,
  author = {Svaton, Martin and Knetki-Wroblewska, Magdalena and Hosek, Petr and Chowaniecova, Gabriela and Spacek, Jan and Fischer, Ondrej and Bilek, Ondrej and Hrnciarik, Michal and Kauffmann-Guerrero, Diego},
  title = {Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study},
  journal = {Journal of Cancer},
  year = {2025},
  volume = {16},
  number = {10},
  pages = {3015--3023},
  doi = {10.7150/jca.113815}
}
Start for free →